Sarcoma Oncology Research Center

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Sarcoma11 trials
• Childhood cancers7 trials
• Lung cancer1 trial
• Melanoma1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial

Phase

• Phase 1/25 trials
• Phase 13 trials
• Phase 23 trials
• Phase 2/32 trials

Status

• Terminated6 trials
• Active, not recruiting4 trials
• Recruiting3 trials
• Completed1 trial
• Withdrawn1 trial

Lead sponsor

• Sarcoma Oncology Research Center, LLC4 trials
• Pfizer2 trials
• Aadi Bioscience, Inc.1 trial
• ADC Therapeutics S.A.1 trial
• Ascentage Pharma Group Inc.1 trial
• and 6 more

Running trials

• Recruiting

  A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

  NCT06678659· Phase 1/2· Recursion Pharmaceuticals Inc.· Source

  Contact: Victoria Chua

• Recruiting

  Metastatic Leiomyosarcoma Biomarker Protocol

  NCT05653388· University of Michigan Rogel Cancer Center· Source

  Contact: Allyssa Lingad

• Active, not recruiting

  A Study of AL102 in Patients With Progressing Desmoid Tumors

  NCT04871282· Phase 2/3· Immunome, Inc.· Source

• Active, not recruiting

  SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

  NCT03778996· Phase 2· Sarcoma Oncology Research Center, LLC· Source

• Active, not recruiting

  Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

  NCT04165330· Phase 1/2· Sarcoma Oncology Research Center, LLC· Source

• Active, not recruiting

  A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

  NCT03611868· Phase 1/2· Ascentage Pharma Group Inc.· Source

• Recruiting

  SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

  NCT03138161· Phase 1/2· Sarcoma Oncology Research Center, LLC· Source

  Contact: Erlinda M Gordon, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Sarcoma2 recruiting

Closed trials

• Withdrawn

  Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures

  NCT05869994· Sarcoma Oncology Research Center, LLC· Source

• Terminated

  Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

  NCT05261490· Phase 1/2· Pfizer· Source

• Terminated

  A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

  NCT05389462· Phase 1· ADC Therapeutics S.A.· Source

• Terminated

  A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

  NCT05269355· Phase 2/3· PTC Therapeutics· Source

• Terminated

  A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

  NCT05355753· Phase 1· C4 Therapeutics, Inc.· Source

• Completed

  Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

  NCT05103358· Phase 2· Aadi Bioscience, Inc.· Source

• Terminated

  A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma

  NCT04996004· Phase 2· Pfizer· Source

• Terminated

  Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

  NCT04204941· Phase 1· Epizyme, Inc.· Source